Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker CORT
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Daniel N. Swisher Jr. Director | CORT Corcept Therapeutics Incorporated | Sale | 1,500 | $74.07 | $111.1K Sale | Form 4 ↗ |
| Nov 3, 2026 | Sean Maduck | CORT Corcept Therapeutics Incorporated | Sale | 4,542 | $82.68 | $375.5K Sale | Form 4 ↗ |
| Nov 3, 2026 | Sean Maduck | CORT Corcept Therapeutics Incorporated | Sale | 8,617 | $82.02 | $706.8K Sale | Form 4 ↗ |
| Nov 2, 2026 | Sean Maduck | CORT Corcept Therapeutics Incorporated | Sale | 11,841 | $81.42 | $964.1K Sale | Form 4 ↗ |
| Nov 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | CORT Corcept Therapeutics Incorporated | Sale | 1,676 | $81.52 | $136.6K Sale | Form 4 ↗ |
| Nov 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | CORT Corcept Therapeutics Incorporated | Sale | 6,657 | $80.73 | $537.4K Sale | Form 4 ↗ |
| Oct 15, 2026 | James N. Wilson Director | CORT Corcept Therapeutics Incorporated | Sale | 300 | $116.30 | $34.9K Sale | Form 4 ↗ |
| Oct 15, 2026 | James N. Wilson Director | CORT Corcept Therapeutics Incorporated | Sale | 3,046 | $115.39 | $351.5K Sale | Form 4 ↗ |
| Oct 15, 2026 | James N. Wilson Director | CORT Corcept Therapeutics Incorporated | Sale | 6,654 | $114.48 | $761.7K Sale | Form 4 ↗ |
| Sep 16, 2026 | Roberto Wandenkolk Vieira President, Oncology | CORT Corcept Therapeutics Incorporated | Sale | 296 | $100.82 | $29.8K Sale | Form 4 ↗ |
| Sep 15, 2026 | James N. Wilson Director | CORT Corcept Therapeutics Incorporated | Sale | 2,800 | $111.70 | $312.8K Sale | Form 4 ↗ |
| Sep 15, 2026 | James N. Wilson Director | CORT Corcept Therapeutics Incorporated | Sale | 400 | $110.84 | $44.3K Sale | Form 4 ↗ |
| Sep 15, 2026 | James N. Wilson Director | CORT Corcept Therapeutics Incorporated | Sale | 6,800 | $110.27 | $749.8K Sale | Form 4 ↗ |
| Sep 14, 2026 | Joseph Douglas Lyon See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 2,188 | $114.12 | $249.7K Sale | Form 4 ↗ |
| Sep 14, 2026 | Joseph Douglas Lyon See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 7,812 | $113.32 | $885.3K Sale | Form 4 ↗ |
| Sep 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | CORT Corcept Therapeutics Incorporated | Sale | 1,225 | $115.44 | $141.4K Sale | Form 4 ↗ |
| Sep 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | CORT Corcept Therapeutics Incorporated | Sale | 5,621 | $114.58 | $644.1K Sale | Form 4 ↗ |
| Sep 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | CORT Corcept Therapeutics Incorporated | Sale | 1,606 | $113.72 | $182.6K Sale | Form 4 ↗ |
| Sep 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | CORT Corcept Therapeutics Incorporated | Sale | 974 | $112.40 | $109.5K Sale | Form 4 ↗ |
| Sep 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | CORT Corcept Therapeutics Incorporated | Sale | 1,537 | $111.37 | $171.2K Sale | Form 4 ↗ |
| Sep 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | CORT Corcept Therapeutics Incorporated | Sale | 23,770 | $110.70 | $2.6M Sale | Form 4 ↗ |
| Sep 2, 2026 | Roberto Wandenkolk Vieira President, Oncology | CORT Corcept Therapeutics Incorporated | Sale | 23,600 | $109.35 | $2.6M Sale | Form 4 ↗ |
| Sep 1, 2026 | Sean Maduck See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 2,281 | $115.61 | $263.7K Sale | Form 4 ↗ |
| Sep 1, 2026 | Sean Maduck See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 10,989 | $114.71 | $1.3M Sale | Form 4 ↗ |
| Sep 1, 2026 | Sean Maduck See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 11,730 | $113.94 | $1.3M Sale | Form 4 ↗ |
| Aug 26, 2026 | Kimberly Park Director | CORT Corcept Therapeutics Incorporated | Sale | 26,685 | $122.55 | $3.3M Sale | Form 4 ↗ |
| Aug 25, 2026 | Sean Maduck See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 5,870 | $126.06 | $740.0K Sale | Form 4 ↗ |
| Aug 25, 2026 | Sean Maduck See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 25,085 | $125.47 | $3.1M Sale | Form 4 ↗ |
| Aug 18, 2026 | David L. Mahoney Director | CORT Corcept Therapeutics Incorporated | Sale | 400 | $119.64 | $47.9K Sale | Form 4 ↗ |
| Aug 18, 2026 | David L. Mahoney Director | CORT Corcept Therapeutics Incorporated | Sale | 7,055 | $118.88 | $838.7K Sale | Form 4 ↗ |
| Aug 18, 2026 | David L. Mahoney Director | CORT Corcept Therapeutics Incorporated | Sale | 91,167 | $118.24 | $10.8M Sale | Form 4 ↗ |
| Aug 18, 2026 | David L. Mahoney Director | CORT Corcept Therapeutics Incorporated | Sale | 4,984 | $117.47 | $585.5K Sale | Form 4 ↗ |
| Aug 17, 2026 | Gary Charles Robb Chief Business Officer | CORT Corcept Therapeutics Incorporated | Sale | 10,000 | $116.26 | $1.2M Sale | Form 4 ↗ |
| Aug 14, 2026 | Sean Maduck See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 3,664 | $114.49 | $419.5K Sale | Form 4 ↗ |
| Aug 14, 2026 | James N. Wilson Director | CORT Corcept Therapeutics Incorporated | Sale | 2,279 | $112.64 | $256.7K Sale | Form 4 ↗ |
| Aug 14, 2026 | James N. Wilson Director | CORT Corcept Therapeutics Incorporated | Sale | 4,668 | $111.44 | $520.2K Sale | Form 4 ↗ |
| Aug 14, 2026 | James N. Wilson Director | CORT Corcept Therapeutics Incorporated | Sale | 3,053 | $110.49 | $337.3K Sale | Form 4 ↗ |
| Aug 10, 2026 | Sean Maduck See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 1,031 | $114.52 | $118.1K Sale | Form 4 ↗ |
| Aug 10, 2026 | William Guyer Chief Development Officer | CORT Corcept Therapeutics Incorporated | Sale | 4,770 | $114.04 | $544.0K Sale | Form 4 ↗ |
| Aug 10, 2026 | William Guyer Chief Development Officer | CORT Corcept Therapeutics Incorporated | Sale | 11,530 | $113.18 | $1.3M Sale | Form 4 ↗ |
| Aug 4, 2026 | William Guyer Chief Development Officer | CORT Corcept Therapeutics Incorporated | Sale | 3,700 | $113.12 | $418.5K Sale | Form 4 ↗ |
| Aug 3, 2026 | Sean Maduck See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 20,305 | $114.70 | $2.3M Sale | Form 4 ↗ |
| Aug 3, 2026 | Joseph Douglas Lyon See Remarks | CORT Corcept Therapeutics Incorporated | Sale | 1,540 | $114.16 | $175.8K Sale | Form 4 ↗ |
| Jul 30, 2026 | Atabak Mokari Chief Financial Officer | CORT Corcept Therapeutics Incorporated | Sale | 1,001 | $120.67 | $120.8K Sale | Form 4 ↗ |
| Jul 30, 2026 | Atabak Mokari Chief Financial Officer | CORT Corcept Therapeutics Incorporated | Sale | 8,103 | $119.95 | $972.0K Sale | Form 4 ↗ |
| Jul 30, 2026 | Atabak Mokari Chief Financial Officer | CORT Corcept Therapeutics Incorporated | Sale | 4,783 | $118.73 | $567.9K Sale | Form 4 ↗ |
| Jul 30, 2026 | Atabak Mokari Chief Financial Officer | CORT Corcept Therapeutics Incorporated | Sale | 8,267 | $117.93 | $974.9K Sale | Form 4 ↗ |
| Jul 30, 2026 | Atabak Mokari Chief Financial Officer | CORT Corcept Therapeutics Incorporated | Sale | 7,089 | $116.96 | $829.1K Sale | Form 4 ↗ |
| Jul 30, 2026 | Atabak Mokari Chief Financial Officer | CORT Corcept Therapeutics Incorporated | Sale | 14,222 | $115.87 | $1.6M Sale | Form 4 ↗ |
| Jul 30, 2026 | Atabak Mokari Chief Financial Officer | CORT Corcept Therapeutics Incorporated | Sale | 15,477 | $114.96 | $1.8M Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:14 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances